Topical TMB-001 Disappoints in Phase 3 Congenital Ichthyosis Trial
TMB-001 did not meet the primary and key secondary endpoints in a randomized, double-blind period of the phase 3 ASCEND clinical trial of congenital ichthyosis. The trial results do not support submission of a New Drug Application to the U.S. Food and Drug Administration, according to Leo Pharma and Timber Pharmaceuticals. The trial did not […]